[1] Ruggiero S, Woo V, Mehrotra B, et al.Osteonecrosis of the jaws associated with the use of bisphosphonate medications: a report of 60 cases[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2004, 98(2): 196-197. [2] Marx RE, Sawatari Y, Fortin M, et al.Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment[J]. J Oral Maxillofac Surg, 2005,63(11): 1567-1575. [3] Watters AL, Hansen HJ, Williams T, et al.Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(2): 192-200. [4] Jann J, Gascon S, Roux S, et al. Influence of the TGF-β superfamily on osteoclasts/osteoblasts balance in physiological and pathological bone conditions[J]. Int J Mol Sci, 2020, 21(20): 7597.e1-7597.e54. [5] Lai K, Xi Y, Du X, et al. Activation of Nell-1 in BMSC sheet promotes implant osseointegration through regulating Runx2/Osterix axis[J]. Front Cell Dev Biol, 2020, 8: 868.e1-868.e11. [6] Khosla S, Burr D, Cauley J, et al.Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research[J]. J Bone Miner Res, 2007, 22(10): 1479-1491. [7] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update[J]. J Oral Maxillofac Surg, 2014,72(10):1938-1956. [8] Badros A, Weikel D, Salama A, et al.Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors[J]. J Clin Oncol, 2006, 24(6): 945-952. [9] Demircan S, Isler SC.Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: a case control study[J]. Niger J Clin Pract, 2020, 23(2): 154-158. [10] Gao SY, Lin RB, Huang SH, et al.PDGF-BB exhibited therapeutic effects on rat model of bisphosphonate-related osteonecrosis of the jaw by enhancing angiogenesis and osteogenesis[J]. Bone, 2021,144: 115117. [11] Wei X, Pushalkar S, Estilo C, et al.Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw[J]. Oral Dis, 2012, 18(6): 602-612. [12] English BC, Baum CE, Adelberg DE, et al.A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer[J]. Ther Clin Risk Manag, 2010, 6: 579-583. [13] Kuroshima S, Sasaki M, Sawase T.Medication-related osteonecrosis of the jaw: a literature review[J]. J Oral Biosci, 2019, 61(2): 99-104. [14] Dong W, Qi M, Wang Y, et al.Zoledronate and high glucose levels influence osteoclast differentiation and bone absorption via the AMPK pathway[J]. Biochem Biophys Res Commun, 2018, 505(4): 1195-1202. [15] 潘剑, 王杞章, 刘济远. 双磷酸盐相关性颌骨坏死[J]. 华西口腔医学杂志, 2017, 35(1): 29-36. [16] Huang J, Liu L, Jin S, et al.Proanthocyanidins promote osteogenic differentiation of human periodontal ligament fibroblasts in inflammatory environment via suppressing NF-κB signal pathway[J]. Inflammation, 2020, 43(3): 892-902. [17] Zhao Y, Wang L, Liu Y, et al.Technetium-99 conjugated with methylene diphosphonate ameliorates ovariectomy-induced osteoporotic phenotype without causing osteonecrosis in the jaw[J]. Calcif Tissue Int, 2012, 91(6): 400-408. [18] Hokugo A, Kanayama K, Sun S, et al.Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice[J]. Bone, 2019, 123: 115-128. |